Eli Lilly's Trulicity nabs novel CV approval in patients with or without established disease
Eli Lilly's Trulicity is in a heated battle with Novo's Ozempic for supremacy in the GLP-1 market. (Eli Lilly)
Analysts and investors were less than amazed when Eli Lilly revealed cardiovascular outcomes data for its GLP-1 diabetes med Trulicity in late 2018. It wasn't that the study didn't hit its mark, they argued, but that the results weren't impressive enough to move the needle in a competitive field.
But the data was impressive enough to score Trulicity a first-of-its-kind approval from the FDA, potentially putting analysts' worries to rest.
The FDA on Friday approved Trulicity to reduce the risk of cardiovascular events in Type 2 diabetes patients with—or without—established CV disease, Lilly said in a release.
Veeva 2020 Unified Clinical Operations Survey
We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.
The approval marks a win for Lilly after results from Trulicity's Rewind CV outcomes trial failed to win over skeptical analysts when top-line results came out in November 2018.